ERBB2 and biliary tract neoplasm: In a cohort of 34 patients with biliary tract cancer, actionable variants were detected in IDH1/2 (18%), followed by FGFR1/2 (16%), EGFR or ERBB2/3 (16%), PTEN (14%), MDM2 (10%), and PIK3CA (10%).